Figure 1.

Genome‐wide CRISPR Cas9 knockout screen identifies FBXO42 leading to trametinib resistance in NRAS‐mutant melanoma. (a, b) Screen outline and hits, FBXO42 was found in 14 independent clones, and MAP3K1 was found in one clone out of the 14 as was TRIM4. (c,d) Immunoblot analysis of FBXO42 gene perturbation efficiency of Cas9 sgRNAs in SK‐MEL‐147 and MZ‐MEL‐2 NRAS‐mutant melanoma cell lines. Ratios of FBXO42 to GAPDH and tubulin levels were generated using Image Lab (Bio‐Rad). (e) SK‐MEL‐147 and MZ‐MEL‐2 cells were treated with 100 nM trametinib and stained with crystal violet 10 days later